![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
AcelRX Pharmaceuticals Inc | NASDAQ:ACRX | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.86 | 0.861 | 0.89 | 0 | 01:00:00 |
Delaware
|
001-35068
|
41-2193603
|
||
(State of incorporation)
|
(Commission File No.)
|
(IRS Employer Identification No.)
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common Stock, $0.001 par value
|
ACRX
|
The Nasdaq Global Market
|
Named Executive Officer
|
Time-Based Stock
Options (1)
|
Restricted Stock Units (2)
|
Vincent J. Angotti,
President and Chief
Executive Officer
|
780,000
|
390,000
|
Pamela Palmer, M.D.,
Ph.D., Chief Medical
Officer
|
245,000
|
122,500
|
Raffi Asadorian, Chief Financial Officer
|
235,000
|
117,500
|
Badri Dasu, Chief Engineering Officer
|
195,000
|
97,500
|
(1)
|
The time-based stock options shall vest as follows: one-fourth (1/4) shall vest on the one year anniversary of the date of grant, and the remaining options shall vest in equal monthly installments over the remaining 36 months, in all cases subject to the person’s Continuous Service (as defined in the Plan).
|
(2)
|
The restricted stock units shall vest in three equal consecutive annual installments on February 11, 2023, February 11, 2024 and February 11, 2025, in all cases subject to the person’s Continuous Service (as defined in the Plan).
|
Date: February 14, 2022
|
ACELRX PHARMACEUTICALS, INC.
|
|
|
|
|
|
|
|
|
|
|
|
By:
|
/s/ Raffi Asadorian
|
|
|
|
Raffi Asadorian
|
|
|
|
Chief Financial Officer
|
|
1 Year AcelRX Pharmaceuticals Chart |
1 Month AcelRX Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions